Philippe Aftimos, MD · @aftimosp · X·· 1 天前评分70
正文 · 原文
🔹CDK4 selective inh Atirmociclib + fulvestrant improved mPFS vs investigator’s choice post-CDK4/6i in the FourLight-1 ph2 trial
🔹Neutropenia the most frequent AE & 1 related pneumontis death
🔹Next step: the FourLight-3 ph3 study in the 1L vs CDK4/6i
#ESMO26 #ESMOAmbassadors
166 浏览 · 1 赞 · 1 转发 · 1 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org帖内回复
- Philippe Aftimos, MD @aftimosp
Next steps: ❓Atirmociclib replacing CDK4/6i in triplets with ET and PIK3CAi? ❓Atirmociclib in the adjuvant setting? #ESMO26 #ESMOAmbassadors @myESMO
来源：Philippe Aftimos, MD · x.com